| DIRECT COMPETITOR COMPARISON | |
| HALO | Pvt1 | Pvt2 | Pvt3 | Industry | | Market Cap: | 575.54M | N/A | N/A | N/A | 109.35M | | Employees: | 129 | 9,0001 | N/A | 1032 | 68 | | Qtrly Rev Growth (yoy): | 23.00% | N/A | N/A | N/A | 19.10% | | Revenue (ttm): | 10.29M | 1.50B1 | N/A | 31.00M2 | 13.84M | | Gross Margin (ttm): | 97.29% | N/A | N/A | N/A | 65.67% | | EBITDA (ttm): | -61.47M | N/A | N/A | N/A | -11.53M | | Oper Margins (ttm): | -610.41% | N/A | N/A | N/A | -149.46% | | Net Income (ttm): | -62.52M | N/A | N/A | N/A | N/A | | EPS (ttm): | -0.743 | N/A | N/A | N/A | -0.31 | | P/E (ttm): | N/A | N/A | N/A | N/A | 20.53 | | PEG (5 yr expected): | N/A | N/A | N/A | N/A | 1.35 | | P/S (ttm): | 53.98 | N/A | N/A | N/A | 9.90 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.79 | -0.75% | 57.48B | 12.39 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 53.43 | 0.09% | 15.45B | 17.88 | | Genzyme Corp. | GENZ | 48.97 | 1.51% | 13.00B | 27.92 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 44.76 | 3.47% | 40.28B | 17.31 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 52.42 | 1.65% | 9.35B | 1069.80 | | Teva Pharmaceutical Industries Limited | TEVA | 57.20 | 0.25% | 50.39B | 52.33 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 40.02 | 0.33% | 4.25B | 20.63 | | King Pharmaceuticals Inc. | KG | 12.68 | 1.12% | 3.15B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.34 | -0.97% | 5.60B | 112.52 | | Pfizer Inc. | PFE | 18.60 | -0.32% | 150.09B | 15.45 | | Johnson & Johnson | JNJ | 64.45 | 0.81% | 177.82B | 14.08 | | GlaxoSmithKline plc | GSK | 41.34 | -1.17% | 104.80B | 13.51 | | Sanofi-Aventis | SNY | 40.28 | -0.05% | 105.18B | N/A | | Novartis AG | NVS | 52.37 | -0.36% | 118.94B | 15.68 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 43.62 | 0.88% | N/A | N/A | | AstraZeneca plc | AZN | 46.08 | -0.80% | 66.82B | 9.25 | | Abbott Laboratories | ABT | 54.32 | 0.56% | 84.02B | 14.72 | | Bristol-Myers Squibb Co. | BMY | 25.22 | -0.04% | 49.96B | 13.05 |
|
| NEWS ON DIRECT COMPETITORS | | No News on Direct Competitors |
|
|